Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Taskforce Agrees to Squeeze Social Security Budget by 140 Billion Yen
October 19, 2016
- Opdivo Ordered to Add Immune Thrombocytopenic Purpura in ADR List
October 19, 2016
- Concomitant Use of Warfarin and Florid Contraindicated: MHLW
October 19, 2016
- Health Minister Nudges Kaketsuken on Biz Handover to Astellas
October 19, 2016
- Urgent Need for Rule on Interim NHI Price Revisions; Current System Unable to Respond in Case of Add’l Indications: MOF Budget Examiner
October 19, 2016
- MHLW Panel to Review Ono’s Etelcalcetide on Oct. 31
October 18, 2016
- Govt to Stockpile Qinghai Strain Pre-Pandemic Flu Vaccines
October 18, 2016
- Govt Panel Member Pushes 50%-Plus Cut for Opdivo Price
October 17, 2016
- MHLW Panel to Discuss Opdivo for Hodgkin’s Lymphoma on Oct. 27
October 17, 2016
- Huge Costs, Amount of Application Data Required Will Be Major Challenges in Development of Biosimilars: Open Forum
October 14, 2016
- Health Minister to “Positively Consider” Setting Biosimilars Use Target
October 14, 2016
- AMED to Open Office in Washington D.C.
October 13, 2016
- 30% of Rejected Requests for Health Damage Compensation Due to Improper Drug Use: MHLW
October 12, 2016
- MHLW Study Group to Revise 75 Manuals on Serious ADRs in 19 Fields Over 5-Year Period
October 12, 2016
- MHLW to Consider Additional Penalties for Kaketsuken after Reviewing Its Report: Minister Shiozaki
October 11, 2016
- Current Information Disclosure for DPO Discussions Appropriate: Shiozaki
October 7, 2016
- Univ. of Tokyo and Kyoto Univ. Selected to Participate in Project to Train Biostatisticians: AMED
October 7, 2016
- Make “High-Level Investment” Credits Permanent under R&D Tax Break: Industry
October 6, 2016
- Chuikyo Green-Lights Basic Plans on “Optimal Use Guidelines,” Notification Letters
October 6, 2016
- Chuikyo OKs Application of Huge-Seller Re-Pricing to Opdivo; Payers Loath to Use Ono Sales Outlook for Calculation
October 6, 2016
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…